Pharmacoeconomics is in the process of becoming a key stage to drug development. It was already so because of its indispensability for access to reimbursement by the paying agencies, the evaluation of the reimbursement rate and the setting of the marketing price. 

Because of the marketing access of biotechnology by-products applicable to oncology or to CNS diseases, most of the time in niche indications prone to develop, it is clear that today, requirements for the granting of price and reimbursement claims are rising in range.


Also, in what should be called the "contract" established between paying agencies, the need to consider other parameters, including clinical-econometric performance criteria, is enhanced.

If the "cost containment" systems are specific to each country and have evolved on the basis of their respective historical and political considerations, those responsible for "Health Economics" are striving to restrict the access to market for drugs that do not provide a real added value.

It is, however, important to be able to determine this latter with precision, which implies the implementation of powerful studies that will have the full agreement of the authorities.

In the framework of this new Pharmacoeconomics, ICTA offers:

  • The set-up of advisory committees,
  • The set-up and the achievement of targeted classical, epidemiological and pharmacoeconomic studies,
  • Pharmaco-economic modelling aggregating all of the data made available,
  • The pharmacoepidemiological follow-up of the drug in real life,
  • Quality of life assessment